199 related articles for article (PubMed ID: 28213878)
21. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.
Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726
[TBL] [Abstract][Full Text] [Related]
22. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
23. Peripheral oxytocin treatment affects the rat adreno-medullary catecholamine content modulating expression of vesicular monoamine transporter 2.
Jovanovic P; Spasojevic N; Stefanovic B; Bozovic N; Jasnic N; Djordjevic J; Dronjak S
Peptides; 2014 Jan; 51():110-4. PubMed ID: 24239562
[TBL] [Abstract][Full Text] [Related]
24. Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism.
Fukumitsu N; Suzuki M; Fukuda T; Kiyono Y; Kajiyama S; Saji H
Nucl Med Biol; 2006 Jan; 33(1):37-42. PubMed ID: 16459257
[TBL] [Abstract][Full Text] [Related]
25. PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine.
Watanabe S; Hanaoka H; Liang JX; Iida Y; Endo K; Ishioka NS
J Nucl Med; 2010 Sep; 51(9):1472-9. PubMed ID: 20720048
[TBL] [Abstract][Full Text] [Related]
26. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats.
Kiyono Y; Iida Y; Kawashima H; Ogawa M; Tamaki N; Nishimura H; Saji H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):999-1005. PubMed ID: 12173012
[TBL] [Abstract][Full Text] [Related]
27. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
29. Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[
Ohshima Y; Sasaki I; Watanabe S; Sakashita T; Higashi T; Ishioka NS
Nucl Med Biol; 2022; 112-113():44-51. PubMed ID: 35802985
[TBL] [Abstract][Full Text] [Related]
30. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
31. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?
Kölby L; Bernhardt P; Johanson V; Wängberg B; Muth A; Jansson S; Forssell-Aronsson E; Nilsson O; Ahlman H
Ann N Y Acad Sci; 2006 Aug; 1073():491-7. PubMed ID: 17102116
[TBL] [Abstract][Full Text] [Related]
32. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.
Kölby L; Bernhardt P; Levin-Jakobsen AM; Johanson V; Wängberg B; Ahlman H; Forssell-Aronsson E; Nilsson O
Br J Cancer; 2003 Oct; 89(7):1383-8. PubMed ID: 14520475
[TBL] [Abstract][Full Text] [Related]
33. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
34. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes.
Kiyono Y; Iida Y; Kawashima H; Tamaki N; Nishimura H; Saji H
Eur J Nucl Med; 2001 Jul; 28(7):894-9. PubMed ID: 11504086
[TBL] [Abstract][Full Text] [Related]
35. Norepinephrine Transporter as a Target for Imaging and Therapy.
Pandit-Taskar N; Modak S
J Nucl Med; 2017 Sep; 58(Suppl 2):39S-53S. PubMed ID: 28864611
[TBL] [Abstract][Full Text] [Related]
36. Spatial Inhomogeneity of Cardiac Norepinephrine Transport Protein and Meta-[
Kusmic C; Giorgetti A; Barsanti C; Burchielli S; Petroni D; Kusch A; Genovesi D; Menichetti L; Marzullo P
Mol Imaging Biol; 2019 Jun; 21(3):482-490. PubMed ID: 30187232
[TBL] [Abstract][Full Text] [Related]
37. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
Pifl C; Reither H; Hornykiewicz O
Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
[TBL] [Abstract][Full Text] [Related]
38. A case of (123)I-MIBG scintigram-negative functioning pheochromocytoma: immunohistochemical and molecular analysis with review of literature.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Yao T
Int J Clin Exp Pathol; 2014; 7(7):4438-47. PubMed ID: 25120831
[TBL] [Abstract][Full Text] [Related]
39. False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma.
Inoue Y; Akahane M; Kitazawa T; Ijichi H; Obi S; Yoshikawa K; Ohtomo K; Omata M
Br J Radiol; 2002 Jun; 75(894):548-51. PubMed ID: 12124245
[TBL] [Abstract][Full Text] [Related]
40. A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.
Vaidyanathan G; Affleck DJ; Norman J; O'Dorisio S; Zalutsky MR
Bioconjug Chem; 2007; 18(6):2122-30. PubMed ID: 17979223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
